| |
|
|
| Cardiac Troponins |
| Troponins of cardiac origin are regulatory proteins that control the calcium mediated interaction of Actin and Myosin. The troponin complex consists of three subunits: Troponin T, which binds to Tropomyosin and facilitates contractions; Troponin I, which binds to Actin and inhibits Actin/Myosin interaction; and Troponin C, which binds the calcium ions . The amino acid sequence of the skeletal and cardiac isoforms of Troponin T and Troponin I are sufficiently dissimilar and therefore detectable by monoclonal antibody assay. Troponin C is not used clinically because both… More... |
 |
|
| |
| The mission of Consultants in Laboratory Medicine of Greater Toledo is to be the provider of choice in anatomic pathology and laboratory medicine consultative services becoming an essential part of the medical team. We desire to positively impact the delivery of healthcare in the community by providing leading edge, highly relevant and personalized laboratory medicine. These related services are knit tightly with front line physician practice, through application of expert knowledge and information technologies to address present and emerging needs. We provide diagnostic and consultative services with unrelenting passion to provide unsurpassed quality as a valued member of the care giving team. |
| |
|
| Medscape Pathology News | Sun, 20 May 2012 06:18:48 EDT
| | More Patients, More Revenue, but Less Rush. How? | | Thu, 17 May 2012 09:00:00 EDT | Doctors may think the only way to increase revenue is to add services, do more marketing, and change their practice. But there are ways to make more money by adapting what you're already doing. Here's how.
Medscape Business of Medicine | | | | Top 10 Cloud-Based EHRs | | Tue, 15 May 2012 18:26:33 EDT | CureMD is tops among companies that sell EHRs as online software that physicians access solely through a Web browser, says research firm KLAS.
Medscape Medical News | | | | Crossing Boundaries in Molecular Therapy: HER2 in ALL | | Tue, 15 May 2012 11:21:03 EDT | Looking at a recent report describing the use of trastuzumab in HER2-positive ALL, Dr. Maurie Markman considers what this means for the future of molecular-targeted cancer therapy.
Medscape Hematology-Oncology | | |
|
